Related Experiment Video

Updated: Feb 13, 2026

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
09:41

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

12.5K

MicroRNA-214 Suppresses Ovarian Cancer by Targeting β-Catenin

Yang Liu1, Jie Lin2, Shujuan Zhai1

  • 1Department of Gynecology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China.

Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|February 28, 2018
PubMed
Abstract

Insights

MicroRNA-214 (miR-214) is downregulated in ovarian cancer and acts as a tumor suppressor. Its overexpression inhibits cancer cell invasion and proliferation by targeting the beta-catenin pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Expression

Background:

  • Ovarian cancer presents a high mortality rate with limited therapeutic options.
  • Novel therapeutic targets are crucial for effective ovarian cancer treatment.
  • The role of microRNA-214 (miR-214) in ovarian cancer requires further investigation.

Purpose of the Study:

  • To investigate the role of miR-214 in ovarian cancer.
  • To determine if miR-214 functions as a tumor suppressor in ovarian cancer.
  • To elucidate the molecular mechanisms underlying miR-214's function in ovarian cancer.

Main Methods:

  • Real-time PCR and Western blot were used to measure miR-214, beta-catenin, cyclin D1, and c-Myc expression.
  • Colony formation and Transwell assays assessed cancer cell invasion and proliferation.
  • Flow cytometry analyzed cell cycle progression.

Main Results:

  • miR-214 expression was significantly lower in ovarian cancer cell lines compared to normal ovarian epithelial cells.
  • Low miR-214 expression correlated with higher pathological grade in ovarian cancer.
  • Overexpression of miR-214 suppressed ovarian cancer cell proliferation, invasion, and induced G0/G1 phase arrest, while downregulating beta-catenin, cyclin D1, and c-Myc.

Conclusions:

  • miR-214 exhibits tumor-suppressive properties in ovarian cancer.
  • miR-214 targets the beta-catenin signaling pathway in ovarian cancer.
  • miR-214 represents a potential therapeutic target for ovarian cancer treatment.
Keywords:
Microrna-214Ovarian cancerTumor suppressorβ-catenin

More Related Videos

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

6.3K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
7
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.2K